中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2009年
9期
1578-1579
,共2页
刘焰%沈晓璐%孙晓东%许迅
劉燄%瀋曉璐%孫曉東%許迅
류염%침효로%손효동%허신
干扰素α-2b%角膜炎
榦擾素α-2b%角膜炎
간우소α-2b%각막염
Interferon α-2b%Keratitis
目的 观察重组干扰素α-2b对病毒性角膜炎的临床疗效.方法 476例(489只眼)患者除常规使用高滴度局部抗病毒药物,同时使用重组干扰素α-2b 100万u皮下注射,隔日1次,评价其临床安全性和有效性.结果 患者的总体治愈率为59.1%,由高到低依次为基质型、内皮型、上皮型、全角膜型;总体复发率为23.5%,由高到低依次为上皮型、全角膜型、内皮型、基质型.药物的不良反应发生率为10.7%.结论 重组干扰素α-2b能提高病毒性角膜炎的治愈率,降低复发率;100万u的重组干扰素α-2b在眼科临床上应用具有较高的安全性.
目的 觀察重組榦擾素α-2b對病毒性角膜炎的臨床療效.方法 476例(489隻眼)患者除常規使用高滴度跼部抗病毒藥物,同時使用重組榦擾素α-2b 100萬u皮下註射,隔日1次,評價其臨床安全性和有效性.結果 患者的總體治愈率為59.1%,由高到低依次為基質型、內皮型、上皮型、全角膜型;總體複髮率為23.5%,由高到低依次為上皮型、全角膜型、內皮型、基質型.藥物的不良反應髮生率為10.7%.結論 重組榦擾素α-2b能提高病毒性角膜炎的治愈率,降低複髮率;100萬u的重組榦擾素α-2b在眼科臨床上應用具有較高的安全性.
목적 관찰중조간우소α-2b대병독성각막염적림상료효.방법 476례(489지안)환자제상규사용고적도국부항병독약물,동시사용중조간우소α-2b 100만u피하주사,격일1차,평개기림상안전성화유효성.결과 환자적총체치유솔위59.1%,유고도저의차위기질형、내피형、상피형、전각막형;총체복발솔위23.5%,유고도저의차위상피형、전각막형、내피형、기질형.약물적불량반응발생솔위10.7%.결론 중조간우소α-2b능제고병독성각막염적치유솔,강저복발솔;100만u적중조간우소α-2b재안과림상상응용구유교고적안전성.
Objective To observe the clinical effect of interferon on the treatment of virus keratitis. Meth-ods Review and analysis was made of 476 patients with virus keratitis who was treated with high concentration of an-ti-virus eyedrops and one million unit of α-2b interferon, the clinical safety and effect was evaluated. Result The total cure rate was 59. 1%, and the type from high to low is interstitial、endothelial、epithelial and the total cornea. The total recurrence rate is 23.5% ,and the type from high to low is epithelial,the total cornea,endothelial and inter-stitial. The incidence rate of the adverse effect is 10. 7%. Condusion Systemic administration of interferon has a direct anti-virus effect, and it can raise the cure rate of virus keratitis as well as decrease recurrencerate. One million unit of interferon has a high clinical safety and effect.